— Know what they know.
Not Investment Advice
Also trades as: 0LB2.L (LSE) · $vol 0M

SUPN NASDAQ

Supernus Pharmaceuticals, Inc.
1W: -3.5% 1M: -1.8% 3M: -2.9% YTD: -0.2% 1Y: +48.7% 3Y: +40.4% 5Y: +61.7%
$48.21
-1.17 (-2.37%)
 
Weekly Expected Move ±5.0%
$44 $47 $49 $52 $54
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · Alpha Radar Neutral · Power 43 · $2.8B mcap · 54M float · 1.32% daily turnover · Short 40% of daily vol

Cash Flow Trends

Operating Cash Flow
$47M -72.5% ▼
5Y CAGR: -19.3%
Capital Expenditures
$1M -84.6% ▼
5Y CAGR: -17.3%
Free Cash Flow
$46M -73.1% ▼
5Y CAGR: -19.4%
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
$61M +1158.3% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income$53M$61M$1M$74M-$39M
Depreciation & Amort.$33M$86M$85M$80M$90M
Stock-Based Comp.$18M$18M$27M$28M$33M
Change in Working Capital$4M-$24M-$9M-$2M-$75M
Other Non-Cash Items$25M$4M$33M$12M$33M
Operating Cash Flow$127M$117M$111M$172M$47M
— Investing Activities —
Capital Expenditures-$2M-$412K-$551K-$725K-$1M
Acquisitions (Net)-$312M-$14K$0$0-$293M
Investment Purchases-$312M-$407M-$102M-$688M-$476M
Investment Sales$531M$191M$371M$499M$775M
Other Investing$13M$14K$0$9K-$439K
Investing Cash Flow-$82M-$217M$269M-$190M$4M
— Financing Activities —
Net Debt Issuance-$138M$0-$402M$0$0
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$0-$23M-$2M-$3M-$28M
Financing Cash Flow-$130M-$10M-$398M$12M$9M
Net Change in Cash-$85M-$110M-$18M-$6M$61M
Cash End of Period$203M$93M$75M$69M$130M
Free Cash Flow$125M$116M$111M$171M$46M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms